Phase II study of chlorozotocin in islet cell carcinoma. A southwest Oncology Group study.

Abstract

Seventeen patients with islet cell carcinoma received chlorozotocin (CTZ). Nine received 200 mg/m2 IV every 6 weeks and 8 received 100 mg/m2. Responses were seen in eight (2 complete, 5 partial, 1 minor) of 13 patients who had received no prior chemotherapy, and in zero of four who had received prior chemotherapy. Toxicity was mild in most patients and consisted predominantly in myelosuppressions; however, in one patient severe renal failure developed. CTZ may have activity comparable to streptozotocin in this group of patients.

• Authors: R M Bukowski, J D McCracken, S P Balcerzak, C J Fabian
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 11 Issue 1 Pg. 48-50 ( 1983) ISSN: 0344-5704 [Print] Germany
• PMID: 6309425 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• chlorozotocin
• Streptozocin

Topics

• Adenoma, Islet Cell (drug therapy)
• Adult
• Aged
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Pancreatic Neoplasms (drug therapy)
• Streptozocin (adverse effects, analogs & derivatives, therapeutic use)